Medicine:PANORAMIC trial
The Platform Adaptive Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community (PANORAMIC Trial) is a clinical trial in the United Kingdom to test the effectiveness of new antiviral drugs at the early stages of COVID-19 infections.[1][2][3] The study aims to find out if antivirals can prevent the need for hospitalisation and help faster recovery for people aged over 50 and those at higher risk due to underlying health conditions.[4] PANORAMIC is sponsored by the University of Oxford and funded by the National Institute for Health and Care Research (NIHR).[5] The trial was launched in December 2021, and as of June 2022, over 25,000 people are enrolled as participants.[6]
Overview
PANORAMIC is a platform trial[7] that will compare two groups who are having symptoms of COVID: one will receive standard NHS care and the other one will receive standard NHS care plus antiviral treatment. Participants can take part from home online or via phone and the antivirals are delivered to them.[8]
Participants
People can enroll in the study if they had symptoms of COVID (confirmed by a test) less than 5 days prior to enrolling. They have to be either aged 50 or over, or have a preexisting health condition.[8][2]
Treatments
The antivirals tested in the study will be molnupiravir[7] and nirmatrelvir/ritonavir (Paxlovid).[9]
Results
Molnupiravir
In December 2022, results from the trial showed that for higher risk, vaccinated adults molnupiravir does not reduce the chances of hospitalisation and death. However it leads to faster recovery and reduced viral load.[10][11]
See also
References
- ↑ "PANORAMIC". https://www.panoramictrial.org/.
- ↑ 2.0 2.1 "Thousands needed to try a new Covid antiviral treatment". BBC News. 25 January 2022. https://www.bbc.com/news/health-60117313.
- ↑ "Public urged to sign up to world-first COVID-19 antiviral study". https://www.gov.uk/government/news/public-urged-to-sign-up-to-world-first-covid-19-antiviral-study.
- ↑ "Covid cost-cutting will put blinkers on our best Covid research". 21 February 2022. https://www.theguardian.com/world/2022/feb/21/covid-cost-cutting-will-put-blinkers-on-our-best-covid-research.
- ↑ "NIHR funds community COVID-19 antiviral trial". https://www.nihr.ac.uk/news/nihr-funds-community-covid-19-antiviral-trial/29048.
- ↑ Pinching, John (22 February 2022). "PANORAMIC view of World's largest COVID study". https://www.pharmatimes.com/news/panoramic_view_of_worlds_largest_covid_study_1388052.
- ↑ 7.0 7.1 "Over ten thousand participants enrol in world's largest COVID-19 antiviral study". https://www.nihr.ac.uk/news/over-ten-thousand-participants-enrol-in-worlds-largest-covid-19-antiviral-study/29951.
- ↑ 8.0 8.1 "Participant Information — PANORAMIC". https://www.panoramictrial.org/participant-information.
- ↑ "Second ground-breaking antiviral to be deployed to country's most vulnerable". https://www.gov.uk/government/news/second-ground-breaking-antiviral-to-be-deployed-to-countrys-most-vulnerable.
- ↑ Butler, Christopher C; Hobbs, F D Richard; Gbinigie, Oghenekome A; Rahman, Najib M; Hayward, Gail; Richards, Duncan B; Dorward, Jienchi; Lowe, David M et al. (2022-12-22). "Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial" (in en). The Lancet: S0140673622025971. doi:10.1016/S0140-6736(22)02597-1. PMID 36566761.
- ↑ "Pill for Covid does not reduce risk of hospitalisation or death, UK study finds" (in en). 2022-12-22. https://www.theguardian.com/world/2022/dec/22/molnupiravir-pill-for-covid-does-not-reduce-risk-of-hospitalisation-or-death-uk-study-finds.
External links
 |
